Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab

Background & Aims: Immunotherapy with atezolizumab and bevacizumab (a + b) has improved the prognosis of patients with unresectable hepatocellular carcinoma (HCC). However, the outcome for individual patients is highly variable. This study aimed to (i) develop and validate a prognostic predi...

Full description

Bibliographic Details

Published in:	JHEP Reports
Main Authors:	Simon Johannes Gairing, Philipp Mildenberger, Jennifer Gile, Fabian Artusa, Bernhard Scheiner, Catherine Leyh, Sabine Lieb, Friedrich Sinner, Vincent Jörg, Thorben Fruendt, Vera Himmelsbach, Nada Abedin, Cennet Sahin, Katrin Böttcher, Jasmin Schuhbaur, Simon Labuhn, James Korolewicz, Claudia A.M. Fulgenzi, Antonio D'Alessio, Valentina Zanuso, Florian Hucke, Natascha Röhlen, Najib Ben Khaled, Eleonora Ramadori, Lukas Müller, Arndt Weinmann, Roman Kloeckner, Peter Robert Galle, Nguyen H. Tran, Sudhakar K. Venkatesh, Andreas Teufel, Matthias Ebert, Enrico N. De Toni, Dirk-Thomas Waldschmidt, Jens U. Marquardt, Dominik Bettinger, Markus Peck-Radosavljevic, Andreas Geier, Florian P. Reiter, Lorenza Rimassa, David J. Pinato, Christoph Roderburg, Thomas Ettrich, Michael Bitzer, Veit Scheble, Ursula Ehmer, Marie-Luise Berres, Fabian Finkelmeier, Maria Angeles Gonzalez-Carmona, Johann von Felden, Kornelius Schulze, Marino Venerito, Florian van Bömmel, Leonie S. Jochheim, Matthias Pinter, Raphael Mohr, Sumera I. Ilyas, Irene Schmidtmann, Friedrich Foerster
Format:	Article
Language:	English
Published:	Elsevier 2025-03-01
Subjects:	Hepatocellular carcinoma Cirrhosis Systemic therapy Prediction model Outcome PD-L1
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589555924002994